 |
Market Research Report
Global Anti-Infective Drugs Market - 2020-2027 |
||||||
| Published by | DataM Intelligence | Product code | 972292 | ||||
| Published | Content info | Delivery time: 1-2 business days |
|||||
| Price |
|
||||||
| Global Anti-Infective Drugs Market - 2020-2027 | ||
| Published: November 21, 2020 | Content info: |
|
The global anti-infective drugs market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
The anti-infective drugs are described as substances which prevent infectious agents or organisms from spreading. These are mostly communicable diseases spread from viruses, bacteria, fungi, and other organisms. Such infection causing micro-organisms include viruses, bacteria, fungi, viroid, and macro parasites. Infections thus caused can be classified depending on the type of organism causing infection and the symptoms and medical signs shown by host. High prevalence and incidence rates of infectious diseases, especially viral infection, and newer drug introductions have resulted in increase in growth of global anti-infective drugs market. These factors are projected to drive demand for anti-infective drugs in the near future. There are several global players having well-established R&D with increased focus upon development of innovative drugs against multidrug resistant organisms.
The global anti-infective drugs market market growth is driven by the rise awareness among the population about various infectious diseases and the availability of reimbursements to infection treatment in various countries have played a significant role in driving the market. Rise in the number of hospitals and primary care clinics also boosts the demand for anti-infective drugs.
Anti-infectives drugs has been one of the major segment for many pharmaceutical companies from decades. Over the past two decades, the infection rate has grown significantly, particularly across the low and middle income countries. There are a large number of companies well-established in the market with their products in the form of antifungals, antibiotics, anti-bacterial, anti-protozoans and antivirals targeting cytochrome, interleukin, interferons and some are multi-drug resistants. The primary driving factor for the growth of the market is increasing burden of several infectious diseases across developed and emerging markets such as different forms of influenza, diarrhea, hepatitis, and urinary tract infections, among others, which needs more attention from pharmaceutical and biotechnology companies.
Factors like increasing prevalence of infectious diseases and antimicrobial resistance to existing anti-infective agents are estimated to fuel the market growth. Moreover, escalating health-consciousness, about the availability of diagnostics for infectious diseases and avoidable risks associated with the early diagnosis are some of the factors projected to boost the growth.
Companies have recently launched a panel of FDA approved, modified antibiotics for their use in the treatment of acute bacterial skin and soft tissue infections; these drugs include Dalvance (Dalbavancin), Orbactiv (Oritavancin), Sivextro (Tedizolid), and Zevtera (Ceftobiprole). The high penetration of these anti-infective drugs due to their increased efficacy is expected to serve as a growth driver for the anti-infective agents market in the forecast period.
For instance, in 2016, the Food and Drug Administration (FDA) approved drugs, such as Descovy by Gilead, for the treatment of HIV-1 infection and Zepatier by Merck that targets chronic Hepatitis C virus (HCV) genotypes 1 or 4 infections in adults.
On the contrary, ome of the major restraints to this market are high investment costs in R&D, as major importance is given to multi-drug resistant drug, where several companies product fail in the early-stage or clinical stage of development. Also, shortage of resources in healthcare facilities particularly in emerging markets, restricts the growth of this market.
COVID-19 was may have a complex long-term impact on anti-infective resistance. Coordinated strategies at the individual, health-care and policy levels are urgently required to inform necessary actions to reduce the potential longer-term impact on anti-infective and on access to effective antimicrobials. However, the impact of covid-19 on the pharmaceutical industry is projected to be neutralized by certain factors including higher demand for currently marketed drugs including anti-infective.
By product type, the anti-infective drugs market is classified into antibiotics, antivirals, antifungals, other.
Antiviral segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
The antiviral agents are expected to show high growth over the forecast period, as several drug manufacturers are exploring the opportunities to expand in the lower and middle income countries, where epidemic infection rate is high. There is high diversity in patient pool which require long treatment procedures in hospital facilities as well as home care treatments.
Antiviral drugs refer to those prescription medicines that are capable of fighting against flu viruses in one's body. Antiviral drugs could include intravenous solutions, an inhaled powder, liquid, or pills. However, antiviral drugs cannot be purchased just over-the-counter, one would need a prescription for obtaining such drugs. The global antiviral drugs market is likely to observe considerable growth due to the rising incidences of viral infections.
Moreover, there has been observed a growing interest by government in countries showing fast economic growth, to collaborate with hospitals and global pharmaceutical companies to imporve the distribution rate of antiviral agents to the needful in the required area of a country. Such factors are expected to boost the growth of antivirals segment over the forecast period.
On the basis of distribution channel, the Anti-Infective drugs market is classified into hospital pharmacy, pharmacy stores, others.
The hospital pharmacy are expected to dominate the Anti-Infective drugs market during the forecast period
The hospital pharmacies held the largest share in the Anti-Infective drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
North America region holds the largest market share global Anti-Infective drugs market
North America region is dominating the global Anti-Infective drugs market accounted for the largest market share in 2019. The presence of sophisticated healthcare infrastructure and high awareness among end-users such as clinicians and healthcare professionals are estimated to be the key growth drivers. Moreover, high purchasing power for expensive drugs and the presence of favorable reimbursement policies are anticipated to further fuel the regional market during the forecast period.
Asia-Pacific is largest market in terms of share owing to the presence of generics companies and rising economic stability and increasing disposable income. Also, the growing geriatric population coupled with increased susceptibility to infections is expected to provide a potential growth platform in the forthcoming years. India is expected to exhibit high growth potential in terms of demand for anti-infective drugs market due to the presence of a large patient pool, governmental initiatives in undertaking various control programs, and rise in cost containment initiatives by drug manufacturers.
The anti-infective drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories Limited, Cipla Ltd., Claris Life Sciences Ltd., Glenmark Pharmaceuticals Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Lupin Ltd., Panacea Biotech Ltd., Novartis AG, Pfizer Ltd., Ranbaxy Laboratories Ltd., and Sun Pharmaceutical Industries Ltd. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the anti-infective drugs market globally.
Overview: Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.
Product Portfolio: The Company's portfolio comprised 164 products including of API business, an independent subsidiary called Glenmark Life Sciences, Glenmark Pharmaceuticals is focused in the areas of respiratory and dermatology.
The global anti-infective drugs market report would provide an access to an approx. 61 market data table, 56 figures and 240 pages.
LIST NOT EXHAUSTIVE
Anti-Infective Agents Market, By Type, By Distribution Channel, and By Geography - Analysis, Size, Share, Trends, & Forecast from 2021-2027
Anti-infective Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)
Anti-Infective Drugs Global Market Report 2020-30: Covid 19 Implications and Growth
South Africa Anti-Infective Market to 2027 - Regional Analysis and Forecasts by Type ; Range, and Distribution Channel
Anti-infective Agents Market Forecast 2019-2029: Anti-viral, Anti-bacterial, Anti-fungal, Hepatitis, HIV, Pneumonia, Aspergillosis, MRSA, Dermatophytosis, Tuberculosis, Respiratory Virus, Sepsis, Hospital Pharmacies, Retail Pharmacies, Online Sales
Anti-infective Agents Market Size, Share & Trend Analysis By Type (Antibacterial, Antifungal, Antiviral), By Route of Administration (Oral, Topical, IV), By Distribution Channel, And Segment Forecasts, 2019 - 2026
Anti-Infective Drugs Market: By Drug Type ; By Infection Type; and By Geography -Forecast 2019-2024
Anti-Infective Agents - Global Market Outlook (2017-2023)
